Editas Medicine, Inc. Profile Avatar - Palmy Investing

Editas Medicine, Inc.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops …

Biotechnology
US, Cambridge [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Editas Medicine, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of EDIT's Analysis
CIK: 1650664 CUSIP: 28106W103 ISIN: US28106W1036 LEI: - UEI: -
Secondary Listings
EDIT has no secondary listings inside our databases.